Primary mediastinal large B-cell lymphoma in a patient on Fingolimod for relapsing-remitting multiple sclerosis

Mult Scler Relat Disord. 2021 Apr:49:102776. doi: 10.1016/j.msard.2021.102776. Epub 2021 Jan 19.

Abstract

Background: There are multiple case reports in the literature describing an association between fingolimod and cutaneous neoplasms.

Objective: Investigate and report a case of a primary mediastinal large B-cell lymphoma in a patient on fingolimod for Relapsing-Remitting Multiple Sclerosis (RRMS).

Methods: Case Report.

Results: The patient developed a primary mediastinal large B-cell lymphoma after seven years of treatment with fingolimod. The patient is currently in complete remission after cessation of treatment, surgical resection, chemotherapy, and radiation therapy.

Conclusion: This case report highlights the first primary mediastinal large B-cell lymphoma associated with fingolimod treatment. It should be considered a rare, but potential adverse effect of fingolimod.

Keywords: CD30; Fingolimod; Lymphoma; Multiple sclerosis; Primary mediastinal large B-cell lymphoma.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Fingolimod Hydrochloride / adverse effects
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Lymphoma, B-Cell* / complications
  • Lymphoma, B-Cell* / diagnostic imaging
  • Lymphoma, B-Cell* / drug therapy
  • Multiple Sclerosis*
  • Multiple Sclerosis, Relapsing-Remitting* / diagnostic imaging
  • Multiple Sclerosis, Relapsing-Remitting* / drug therapy

Substances

  • Immunosuppressive Agents
  • Fingolimod Hydrochloride